CAR-T Cellular Therapy Development


CAR-T Cellular Therapy Solutions

From optimizing CAR-T cell design and evaluating pre-clinical models to discovering response biomarkers and mechanisms of action, together we can advance the field of cellular therapy and improve the human condition.


See All Publications

Immune Monitoring for Advanced Cell Therapy Trials in Transplantation: Which Assays and When?

A number of immune regulatory cellular therapies, including regulatory T cells and mesenchymal stromal cells, have emerged as novel alternative therapies for the control of transplant alloresponses. Clinical studies have demonstrated their feasibility and safety, however developing our understanding of the impact of cellular therapeutics in vivo requires advanced immune monitoring strategies.

Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.

High expression levels of human epidermal growth factor receptor 2 (HER2) have been associated with poor prognosis in patients with pancreatic adenocarcinoma (PDAC). However, HER2-targeting immunotherapies have been unsuccessful to date.

Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing.

The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient’s leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell populations that might negatively affect production of chimeric antigen receptor (CAR) T cells, such as myeloid cells.

Spotlight on CAR-T

Webinar New Approaches for CAR-T Cell Therapies: Technology Symposium featuring GeoMx spatial profiling and nCounter CAR-T Characterization
Webinar Murine March Madness: Contextual reprogramming of CAR-T cells for the treatment of HER2-expressing cancers
Blog Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog SITC in Focus: CAR-T Cell Therapy
Poster Molecular Characterization for CAR-T Cell Therapy-Poster

Related Resources

View All Resources
Product Bulletin CAR-T – Product Bulletin
Blog Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog SITC in Focus: CAR-T Cell Therapy
Poster CAR-T EU Congress 2019 Poster – A Step Toward Standardization with the nCounter® CAR-T Characterization Panel
Product Bulletin nCounter® Stem Cell Characterization Panel Product Bulletin

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us